[The antidyslipoproteinemic activity of ufibrate in patients with non-insulin-dependent diabetes mellitus].
Ufibrate (150 mg daily) was found to have a beneficial effect on main parameters characterizing lipid metabolism, with no effect being exerted on carbohydrate metabolism, as evidenced by three months' follow-up of 24 patients aged 42 to 65 presenting with insulin-nondependent type II diabetes mellitus and hyperlipidemia. Ufibrate appeared to be a most efficacious long-term drug treatment option, particularly so in those patients presenting with initially high blood levels of a great many of lipid fractions.
Dolzhenko
A T
AT
Nesterov
O M
OM
Petrenko
Ie V
IeV
Larina
T F
TF
Sahalovs'ka
H Iu
HIu
D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D011422:Propionates; C111771:undecyl 2-(4-chlorophenoxy)propionate
Protydyslipoproteïnemidna aktyvnist' ufibratu u khvorykh z insulinnezalezhnym tsukrovym diabetom.